Compare WFG & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFG | ICUI |
|---|---|---|
| Founded | 1955 | 1984 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.6B |
| IPO Year | 2007 | 1995 |
| Metric | WFG | ICUI |
|---|---|---|
| Price | $68.32 | $160.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $89.50 | ★ $169.00 |
| AVG Volume (30 Days) | 168.2K | ★ 210.4K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.96 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $5.05 | N/A |
| Revenue Next Year | $10.26 | $4.46 |
| P/E Ratio | ★ N/A | $85.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $57.34 | $112.50 |
| 52 Week High | $76.99 | $192.85 |
| Indicator | WFG | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 33.73 |
| Support Level | $67.41 | $138.91 |
| Resistance Level | $72.20 | $191.07 |
| Average True Range (ATR) | 2.15 | 4.39 |
| MACD | -0.13 | -2.90 |
| Stochastic Oscillator | 46.04 | 3.98 |
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.